UroGen Pharma (NASDAQ:URGN) Stock Price Up 4.5% – Here’s Why

UroGen Pharma Ltd. (NASDAQ:URGN)’s stock price traded up 4.5% during trading on Wednesday . The stock traded as high as $10.91 and last traded at $11.11. 12,087 shares were traded during mid-day trading, a decline of 98% from the average session volume of 500,716 shares. The stock had previously closed at $10.63.

Analyst Ratings Changes

Several brokerages have recently weighed in on URGN. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Monday, March 10th. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. Finally, HC Wainwright dropped their target price on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $38.20.

UroGen Pharma Price Performance

The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $515.10 million, a PE ratio of -3.56 and a beta of 1.12. The stock has a 50-day moving average price of $10.69 and a 200 day moving average price of $11.46.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. Equities analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

Institutional investors have recently modified their holdings of the business. RTW Investments LP boosted its holdings in UroGen Pharma by 1.3% in the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after purchasing an additional 47,447 shares during the period. Toronto Dominion Bank acquired a new stake in UroGen Pharma in the 4th quarter valued at about $18,628,000. Vestal Point Capital LP boosted its stake in shares of UroGen Pharma by 307.5% in the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock valued at $17,360,000 after buying an additional 1,230,000 shares during the period. Acorn Capital Advisors LLC purchased a new position in shares of UroGen Pharma in the 4th quarter valued at about $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of UroGen Pharma by 2.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock worth $14,667,000 after buying an additional 36,084 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.